ESH Video

2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to Bedside

2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to Bedside
March 05 - March 07, 2021 - E-CONFERENCE, #ESHERYTHRO2021
Chairs : Maria Domenica Cappellini, Stuart Orkin, Valeria Santini

Information

2nd TRANSLATIONAL RESEARCH CONFERENCE
ERYTHROPOIESIS CONTROL AND INEFFECTIVE ERYTHROPOIESIS: FROM BENCH TO BEDSIDE

Chairs: Maria Domenica Cappellini, Stuart Orkin, Valeria Santini

#ESHERYTHRO2021

CONFERENCE UPDATE: novel coronavirus (COVID-19)

In view of continuing COVID-19 related challenges and uncertainties, ESH has decided to hold the 2nd Translational Research Conference 2021 on Erythropoiesis as a virtual event.

Dates of the E-Conference:
Live programme: March 5-7, 2021
On demand programme: February 24 until April 7, 2021.

 

ABOUT THE E-CONFERENCE:

The main objective of this virtual conference is to accompany you from “bench to bedside”, translating recent progress in the understanding of the origin and developmental control of haemopoietic megakaryocytic-erythroid progenitors into clinical practice.

Erythropoiesis is a complex multistep process from the committed erythroid progenitor to the mature red cell, that involves cross talk with other haemopoietic progenitors. Although recent advances have shed light on some components of this process, much still remains to be elucidated, in particular in the context of pathological erythropoiesis and in haematological disorders characterized by ineffective erythropoiesis.

During erythropoiesis, efficient cytoprotective systems are required to limit possible reactive oxygen species (ROS) related toxic effects. The role of these systems is even more important in conditions of ineffective erythropoiesis (IE) such as thalassaemias, sickle cell disease and congenital dyserythropoietic anaemias (CDAs), but also in myelodysplastic syndromes (MDS).

To date, blood transfusions and erythropoiesis stimulating agents (ESAs) such as recombinant EPO, are the frontline therapies for anaemia associated with ineffective erythropoiesis (IE). However, neither of these treatments are without risk and in some cases they are not effective. There is therefore a clinical need for novel agents with different mechanisms of action from those of existing ESAs. Furthermore, gene therapy and genome editing are becoming a reality for some erythropoietic disorders, opening a new therapeutic scenario and creating needs for decision-making approaches and continuing education.

All of these exciting, rapidly evolving issues will be discussed in the translational setting of this e-Conference, supported by the combined expertise of a distinguished faculty of global experts in the field, including basic scientists and clinicians.

The programme of the second ESH meeting on ERYTHROPOIESIS CONTROL AND INEFFECTIVE ERYTHROPOIESIS: FROM BENCH TO BEDSIDE is looking very exciting and we are looking forward to welcoming you!

LEARNING OBJECTIVES:
– Describe the impact of the niche on haematopoietic development and ageing of haematopoietic stem cells
– Describe factors such as metabolism and inflammation/infection influencing the niche and, consequently, haematopoietic stem cells
– The niche in myeloid and lymphoid malignancies
– The impact of immune cells and immunotherapy on the niche
– Concepts and strategies to target haematological malignancies in the niche

MAIN TOPICS:
– Bone marrow response to viral infections
– Hematological response to SARS CoV2 infection
– Dyserythropoiesis in clonal hematopoiesis and MDS
– Erythropoiesis Control
– Iron metabolism and erythropoiesis
– Inherited dyserythropoiesis
– Drugs and ineffective erythropoiesis
– Gene Therapy/Editing

THE PROGRAMME WILL INCLUDE:
– Plenary Sessions
– Simultaneous Meet the Experts Sessions
– Round Table Discussions
– Mentored E-Poster Walks
– Short Oral Communications
– Ample time for in-depth discussion

 

 

Programme

Please click HERE to see the scientific programme.

Abstract submission

 

Abstract Submission for Brief Oral Communications and Poster Presentations

Extended Deadline: January 31st, 2021

CLICK HERE TO SUBMIT YOUR ABSTRACT

 

Guidelines for abstracts:

  • Your abstract can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured. 
  • Maximum number of words: 500 
  • Your abstract will be submitted to peer review.

 

Symposia

Accommodation

Venue

Corporate partners

Scholarships

Workshop

Educational Grants

Registration

The registration fee for the “2nd Translational Research E-Conference: Erythropoiesis Control and Ineffective Erythropoiesis – From Bench to Bedside” is free.

Meet the Expert sessions:  Registration fee:  20€
These sessions will be open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats will be available in each session and pre-registration will therefore be required.

Register Here